International Journal of Neuropsychopharmacology Advance Access published February 25, 2015
EXTENSIVE GREY MATTER VOLUME REDUCTION IN TREATMENT-RESISTANT SCHIZOPHRENIA
Valerie M. Andersona,b, Meghan E. Goldsteina,b, Robert R. Kyddb,c, Bruce R. Russella,b
School of Pharmacy, University of Auckland, Auckland, New Zealand
b
Centre for Brain Research, University of Auckland, Auckland, New Zealand
Department of Psychological Medicine, University of Auckland, Auckland, New Zealand
us cr
c
ip t
a
Category: Regular Research Article
an
Corresponding Author: Valerie Anderson, PhD
Auckland, New Zealand
M
School of Pharmacy, Faculty of Medical & Health Sciences, University of Auckland, Private Bag 92019,
pt ed
Tel: +64 9 923 1914
Fax: +64 9 367 7192
Email: [email protected]
Ac ce
Word Count Abstract: 242 Word Count Text: 4748
Number of References: 54 Number of Figures: 2 Number of Tables: 4
Short Title: Brain loss in treatment-resistant schizophrenia © The Author 2014. Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]
1
ABSTRACT Background: Approximately one third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. This study compared global and regional brain volumes between
ip t
treatment-responders and treatment-resistant patients with schizophrenia, including a group of patients who were clozapine-resistant.
us cr
Methods: T1-weighted brain MRI were obtained on a 3T scanner in 20 controls and 52 people with
schizophrenia who were selected based on their symptomatic response to antipsychotic medication: 18 responding well to first-line atypical antipsychotics (FLR), 19 treatment-resistant but responsive to
an
clozapine monotherapy (TR), and 15 ultra-treatment-resistant who did not respond to clozapine (UTR). Treatment groups were matched for disease duration and current psychopathology. SIENAX
M
and FSL-VBM were used to investigate differences in global brain, grey matter (GM), white matter (WM), ventricular CSF volumes, and regional GM volumes.
pt ed
Results: GM volume was significantly reduced in TR and UTR groups compared with controls and the FLR group (p
EXTENSIVE GREY MATTER VOLUME REDUCTION IN TREATMENT-RESISTANT SCHIZOPHRENIA
Valerie M. Andersona,b, Meghan E. Goldsteina,b, Robert R. Kyddb,c, Bruce R. Russella,b
School of Pharmacy, University of Auckland, Auckland, New Zealand
b
Centre for Brain Research, University of Auckland, Auckland, New Zealand
Department of Psychological Medicine, University of Auckland, Auckland, New Zealand
us cr
c
ip t
a
Category: Regular Research Article
an
Corresponding Author: Valerie Anderson, PhD
Auckland, New Zealand
M
School of Pharmacy, Faculty of Medical & Health Sciences, University of Auckland, Private Bag 92019,
pt ed
Tel: +64 9 923 1914
Fax: +64 9 367 7192
Email: [email protected]
Ac ce
Word Count Abstract: 242 Word Count Text: 4748
Number of References: 54 Number of Figures: 2 Number of Tables: 4
Short Title: Brain loss in treatment-resistant schizophrenia © The Author 2014. Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]
1
ABSTRACT Background: Approximately one third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. This study compared global and regional brain volumes between
ip t
treatment-responders and treatment-resistant patients with schizophrenia, including a group of patients who were clozapine-resistant.
us cr
Methods: T1-weighted brain MRI were obtained on a 3T scanner in 20 controls and 52 people with
schizophrenia who were selected based on their symptomatic response to antipsychotic medication: 18 responding well to first-line atypical antipsychotics (FLR), 19 treatment-resistant but responsive to
an
clozapine monotherapy (TR), and 15 ultra-treatment-resistant who did not respond to clozapine (UTR). Treatment groups were matched for disease duration and current psychopathology. SIENAX
M
and FSL-VBM were used to investigate differences in global brain, grey matter (GM), white matter (WM), ventricular CSF volumes, and regional GM volumes.
pt ed
Results: GM volume was significantly reduced in TR and UTR groups compared with controls and the FLR group (p
